CRISPR blocks RNA, offers hepatitis E treatment path

CRISPR technology has taken another step toward treating viral infections, with researchers at Ruhr University Bochum demonstrating a method to suppress hepatitis E virus replication in human cells. The study, published in JHEP Reports on May 4, 2026, uses the CRISPR/Cas13d system to target viral RNA, a strategy that could address the lack of effective therapies for this disease. Hepatitis E, which causes acute liver inflammation, infects millions globally each year and remains a major public health challenge.

The CRISPR/Cas13d system differs from the widely known Cas9 variant by targeting RNA instead of DNA. Researchers designed short guide RNAs—called crRNAs—that bind to specific sections of the hepatitis E virus genome. “Our approach uses the ability of Cas13 to specifically recognize and destroy viral RNA,” said Yannick Brüggemann, a member of the research team. In lab experiments, this method significantly reduced viral replication and the production of infectious particles without harming host cells.

One key finding involved targeting a region of the virus’s genome called ORF1. crRNAs directed at this area were particularly effective, cutting both the number of infected cells and viral output. “This shows we can attack the virus very specifically without harming the cells,” noted Eike Steinmann. The team’s results suggest that this strategy could minimize collateral damage to healthy tissues, a common concern with antiviral treatments.

Another focus was identifying the minimum number of crRNAs needed to cover multiple viral variants. Bioinformatic analysis revealed that three to four distinct crRNAs could target the majority of known hepatitis E strains. This approach might help counter the virus’s ability to mutate rapidly. “With just a few targeted components, a broad effect can be achieved,” said Emely Richter, highlighting the potential for a versatile treatment.

While the study offers a proof of concept for CRISPR-based antiviral strategies, challenges remain before clinical use. Researchers must address how to deliver the system safely and efficiently within the body. “Further work is needed to optimize delivery for clinical use,” Richter added. The team’s findings, however, mark a significant advance in applying gene-editing tools to combat viral diseases beyond their traditional roles in genetic disorders.

The research team emphasized that their work is still in early stages. No clinical trials have been conducted yet, and the transition from lab results to patient treatments will require years of development. Nevertheless, the study underscores the growing potential of CRISPR technologies in antiviral medicine, particularly for viruses that lack effective treatments. The approach could also be adapted for other RNA-based viruses, opening new possibilities for future research.

The study, titled “Development of a CRISPR-Cas13-based antiviral strategy against hepatitis E virus,” is available in JHEP Reports and includes detailed methodologies and data from cell culture experiments. Researchers are now exploring ways to refine the system for real-world applications, including improving the stability and targeting precision of the crRNAs. For now, the work remains a promising but unproven step toward a new class of therapies.

Hepatitis E infections often resolve on their own, but they can be deadly for pregnant women, people with weakened immune systems, and those without access to clean water. Current treatments are limited to supportive care, making the need for targeted therapies urgent. The Ruhr University team’s findings may provide a foundation for future drugs that directly interfere with viral replication, though significant hurdles remain before such treatments reach patients.

The research highlights the versatility of CRISPR tools, which have been primarily used for editing DNA. By leveraging the RNA-targeting capabilities of Cas13, scientists are expanding the technology’s applications. This shift could lead to innovations in treating not only hepatitis E but also other viral infections, potentially reshaping the landscape of antiviral medicine.

As with any new therapeutic approach, the next steps will involve testing the safety and effectiveness of the CRISPR system in animal models before moving to human trials. Researchers also need to address potential immune responses to the CRISPR components and ensure the system can be delivered effectively to infected tissues. These challenges, while complex, are not insurmountable and represent the next frontier in gene-editing research.